{"id":2244,"date":"2025-12-03T09:03:14","date_gmt":"2025-12-03T08:03:14","guid":{"rendered":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf"},"modified":"2025-12-03T09:03:14","modified_gmt":"2025-12-03T08:03:14","slug":"251203-pr-dextech-medicals-myeloma-study-dose-group-2-and-3","status":"inherit","type":"attachment","link":"https:\/\/dextechmedical.com\/en\/dextech-medicals-myeloma-study-odx-mm-001-dose-group-2-and-dose-group-3\/251203-pr-dextech-medicals-myeloma-study-dose-group-2-and-3\/","title":{"rendered":"251203 &#8211; PR &#8211; DexTech Medical&#8217;s Myeloma Study, Dose Group 2 and 3"},"author":2,"featured_media":0,"comment_status":"","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-2244","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>251203 - PR - DexTech Medical&#039;s Myeloma Study, Dose Group 2 and 3 | DexTech<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"251203 - PR - DexTech Medical&#039;s Myeloma Study, Dose Group 2 and 3 | DexTech\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf\",\"url\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf\",\"name\":\"251203 - PR - DexTech Medical's Myeloma Study, Dose Group 2 and 3 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2025-12-03T08:03:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DexTech Medical&#8217;s Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3\",\"item\":\"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"251203 &#8211; PR &#8211; DexTech Medical&#8217;s Myeloma Study, Dose Group 2 and 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"251203 - PR - DexTech Medical's Myeloma Study, Dose Group 2 and 3 | DexTech","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf","og_locale":"en_US","og_type":"article","og_title":"251203 - PR - DexTech Medical's Myeloma Study, Dose Group 2 and 3 | DexTech","og_url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf","og_site_name":"DexTech","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf","url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf","name":"251203 - PR - DexTech Medical's Myeloma Study, Dose Group 2 and 3 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2025-12-03T08:03:14+00:00","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"DexTech Medical&#8217;s Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3","item":"https:\/\/dextechmedical.com\/dextech-medicals-myelomstudie-odx-mm-001-dosgrupp-2-och-dosgrupp-3\/"},{"@type":"ListItem","position":3,"name":"251203 &#8211; PR &#8211; DexTech Medical&#8217;s Myeloma Study, Dose Group 2 and 3"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf'>251203 - PR - DexTech Medical's Myeloma Study, Dose Group 2 and 3<\/a><\/p>\n"},"caption":{"rendered":"<p>251203 &#8211; PR &#8211; DexTech Medical&#8217;s Myeloma Study, Dose Group 2 and 3<\/p>\n"},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"filesize":245880,"sizes":{}},"post":2243,"source_url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/251203-PR-DexTech-Medicals-Myeloma-Study-Dose-Group-2-and-3.pdf","_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media\/2244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=2244"}]}}